🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New in JAMA Oncology Perioperative Modified FOLFIRINOX for Resectable #PancreaticCancer jamanetwork.com/journals/jamao… Single institution trial from Yale Cancer Center Michael Cecchini Escobar-Hoyos Lab While the perioperative FOLFIRINOX question is mostly settled (trial ran from 2014 to 2021), the

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer JAMA Oncology 10.1001/jamaoncol.2024.1575 🔎 Nonrandomized phs-II 👉46 pts, 72% surgery 👉mPFS 16.7 mo, mOS 37.2 mo 👉Post-op ctDNA + strongly associated with recurrence ESMO - Eur. Oncology

Starting off the session ESMO - Eur. Oncology #ESMO24 Arvind Dasari, MD, MS MD Anderson Cancer Center 👏! Should we revise AJCC staging for #coloncancer with the inclusion of #ctDNA #MRD positivity? The data looks impressive and suggests we need to revise! #cancer #cancerresearch #crcsm

In Trends in Cancer by the MD Anderson Cancer Center team of Scott Kopetz David S. Hong MD Van Morris, MD Advancements in combining targeted therapy and immunotherapy for colorectal cancer cell.com/trends/cancer/…

Catch my latest chat with @TheralDTimpson mendelspod where I discuss how I ventured into the world of #ctdna, what we know so far and what the future holds for #signatera in #crc.

🔬 Exciting insights on the success of ctDNA testing in cancer! 🎧 Listen to this podcast where Adham Jurdi discusses the latest advancements and their impact on personalized medicine. #ctDNA #PersonalizedMedicine #Natera ow.ly/EcmK30sF4uE

MRD testing predicts what will happen with a patient months before CT scans. The Success of ctDNA Testing in Colorectal Cancer: Adham Jurdi (Adham Jurdi) with Natera Oncology mendelspod.com/p/the-success-…

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Can’t wait Myriam Chalabi ! Setting ⏰alarm to see this at 3:10 AM ET !

✳️More data from Galaxy-Japan is highly encouraging for de-escalation arm (MRD - negative) of CIRCULATE-NA and also indicates significant unmet need for MRD positive arm ❗️ ✳️Although this is observational data, the predictive value for ctDNA for appears to be highly promising

Great work by Eric Lander, MD Brandon Huffman, MD Sam Klempner Dr. Cathy Eng Michael Gibson, MD PhD Vanderbilt University. and the Natera team Adham Jurdi and others). Adds to the growing body of evidence re: ctDNA in pts with upper GI cancers.

ctDNA in resected biliary tract cancers - Erman Akkus oncodaily.com/url/220092 JCO Precision Oncology Adham Jurdi Jason W Denbo Mahmoud Ouf, MD Ruth He, MD, PhD #Cancer #GIOnc #BiliaryTractCancers #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

This week, we highlighted research by james Yu, Ruth He, MD, PhD, Mahmoud Ouf, MD, Jason W Denbo, Adham Jurdi, Richard D Kim, and others published in JCO Precision Oncology. Learn more: bit.ly/4262xzh. Georgetown Lombardi Moffitt Cancer Center Natera Oncology

Jonathan A. Nowak #ctDNA analysis of CALGB 80702 adj #celecoxib + FOLFOX in resected, stage III #coloncancer ➡️ Natera Oncology ctDNA status (18.4%+ post-op) prognostic for DFS. ctDNA+ associated w/DFS & OS benefit w/celecoxib vs placebo ASCO #GI25 OncoAlert

Updated data from Dr. Purvl Shah re: BESPOKE trial re: role of #ctDNA and the impact on decision making in stage II/III #coloncancer disease. Natera Oncology @asco #ASCOGI25 #cancer #cancerresearch OncoAlert

#GI25 Love it or hate it, ctDNA is impacting clinical practice! BESPOKE CRC Positive ctDNA with worse outcomes ctDNA status impacting treatment in clinical practice almost 20% of the time! Is this right? Too soon? Regardless, it is happening! Need more data.

#GI25 CALGB 80702 First aspirin and now Celecoxib!? Celecoxib associated with significant association with DFS post resection! HR .55!!!! If these were on-patent molecules would we be seeing these studies yelled from the rooftops? Shocking results in conjunction with the

🧵🧵Happy to share the outcomes of the the #HAI program Eva Selfridge and I built. This was a labor of love and a testament to multidisciplinary collaboration, team building, and trust. Here are my takeaways: sciencedirect.com/science/articl…

In this Oncology Times podcast, Dr. Ruchika Talwar and #Natera’s Dr. @Oncojurdi explore the role of tumor-informed MRD testing in guiding real-time decisions and earlier detection. 🎧 Listen here: ow.ly/svgu50W0Ti3 ASCO #ASCO25

Excited to share this collaborative effort as a poster at #ASCO2025. WES in >5800 GEC shows distinct molecular profiles across anatomical locations in one of the largest cohorts to date. Natera Sam Klempner Dr. Cathy Eng Adham Jurdi #DrMichaelGibson